TELA Bio (TELA)
NASDAQ:TELA
Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.74
$0.04(1.41%)
At close: 4:00 PM EST
$0.74
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.50 - $2.20
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$43.42M
Enterprise Value$59.75M
Total Cash (Recent Filing)$39.54M
Total Debt (Recent Filing)$55.87M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 12, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-1.82
Forecast
1Y Price Target
$2.00Price Target Upside170.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$86.85M
Bulls Say, Bears Say
Bulls Say
Strong Top-line MomentumSustained revenue and unit growth reflect growing surgeon adoption and broader market penetration. Durable demand expansion across procedures and geographies supports scale economics, providing a firmer revenue base that can help dilute fixed costs and enable a multi-quarter path toward improved operating leverage.
High Gross MarginsConsistently healthy gross margins indicate strong product economics for bioengineered implants. Durable margin structure gives the company room to invest in commercialization while preserving the potential for operating profitability as sales scale, assuming SG&A growth moderates relative to revenue gains.
Commercial Expansion And New ProductA fully staffed U.S. salesforce, the April launch of a fully resorbable OviTex LTR, and strong European traction (NHS selection) materially raise addressable market and reimbursement credibility. These structural commercial and product steps support sustained volume growth and broader adoption over coming quarters.
Bears Say
Weakened Balance SheetNegative equity and meaningful debt increase financial vulnerability and limit flexibility. Over a multi-quarter horizon this raises dependency on external funding, could constrain strategic investments, and makes the company more sensitive to higher interest costs and refinancing risk.
Ongoing Cash BurnPersistent negative operating and free cash flow indicates the business is not yet self-funding. Even with improved burn versus prior years, continued cash deficits require financing or rapid commercial acceleration to avoid dilution or capital constraints that could hamper execution over the next several quarters.
Nasdaq Listing RiskA formal Nasdaq deficiency introduces structural regulatory and liquidity risk. Potential delisting or transfer to a lower-tier market can reduce trading liquidity, raise fundraising costs, and distract management, any of which could materially impair access to capital and long-term commercial plans.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.20 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $43.42M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Aug 12, 2026 which is in 72 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on May 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.17.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,766,148 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.00 (170.27% Upside)
$2.00 (170.27% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
-1344.47%
Trailing 12-Months
Asset Growth
-9.53%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed constructive early progress with multiple meaningful positives: fully staffed U.S. commercial team, a major product launch (OviTex LTR), strong international performance (+41% in Europe), 16% unit growth, growing clinical evidence, and a board refresh to support scaling. These highlights were balanced against near-term financial pressures — modest 3% revenue growth in Q1, gross margin compression, a slightly wider net loss driven by higher interest expense, PRS utilization volatility due to concentration risk, and execution/timing risks tied to rep maturation and contract timing. Management expects an inflection in productivity as new hires reach the 6-month mark and reiterated at least 8% full-year revenue growth, signaling confidence in a stronger back half. Overall, the narrative is of early validation and building momentum, but with clear execution risks to realize the projected ramp.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$2.00
▲(170.27% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.48% Insiders
4.91% Mutual Funds
50.68% Other Institutional Investors
20.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---